U.S. markets open in 6 hours 31 minutes

Checkmate Pharmaceuticals, Inc. (CMPI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.40+0.15 (+2.07%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.25
Open7.18
Bid0.00 x 4000
Ask0.00 x 800
Day's Range7.06 - 7.48
52 Week Range6.89 - 23.10
Volume42,489
Avg. Volume47,586
Market Cap159.976M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo
      SmarterAnalyst

      Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo

      Clinical-stage biotechnology company Checkmate Pharmaceuticals Inc. reported data from its Phase 1b trial evaluating the combination of vidutolimod and pembrolizumab for the treatment of advanced anti-PD-1 refractory melanoma. Checkmate Pharmaceuticals’ (CMPI) product candidate vidutolimod is delivered as a biologic virus-like particle. It is designed to trigger the patient’s innate immune system to target tumors in combination with other therapies. Dr. Jason Luke, MD, Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, and Associate Professor of Medicine, University of Pittsburgh School of Medicine, said, “These translational data provide new insights into the rapid pharmacodynamic responses to vidutolimod and support the conclusion that clinical responses to treatment are not associated with the previously-described predictive markers for response to PD-1 blockade such as inflamed tumors.” In the trial, patient response rates to the drug combination were similar across baseline patient characteristics and all of the patients demonstrated the expected rapid induction of anti-Qb antibodies to the virus-like particle. (See Checkmate Pharmaceuticals stock analysis on TipRanks) Furthermore, vidutolimod demonstrated improved response in noninflamed anti-PD-1 refractory melanoma and clinical activity was associated with serum CXCL10. Last month, Jefferies analyst Maury Raycroft reiterated a Buy rating on the stock but lowered the price target to $19 (79.7% upside potential) from $23. Raycroft commented, “CMPI’s lead asset ‘001 is a differentiated TLR9 agonist encapsulated in a virus-like particle in the clinic intended to augment (make cold tumors hot) existing immunotherapies to ultimately broaden efficacy in cancer.” Shares of the healthcare company are down about 28.2% over the last month. Related News: Square Expands To Ireland With Early Access Programme Levi’s 1Q Sales And EPS Beat Estimates; Street Says Buy Provention Bio Shares Crash 40% Due To Regulatory Setback For Diabetes Drug More recent articles from Smarter Analyst: BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination Regeneron’s REGEN-COV Shown To Reduce COVID-19 Progression In Phase 3 Trial AngioDynamics Submits 510(K) Application For AlphaVac System Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens

    • Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
      GlobeNewswire

      Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting

      CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new translational data from Checkmate’s Phase 1b trial of vidutolimod (CMP-001) in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 refractory melanoma and response is associated with serum CXCL10 (Abstract #: 5231: NCT02680184) During the 2021 AACR Virtual Clinical Trials with Novel Immuno-oncology Strategies Session on April 11 from 4:00 – 5:45pm ET, Jason Luke, MD, Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, and Associate Professor of Medicine, University of Pittsburgh School of Medicine, presents new translational data from an ongoing Phase 1b study of vidutolimod in combination with pembrolizumab in patients with PD-1 blockade refractory advanced melanoma. Key highlights from these clinical data include: 93% of patients had progressive disease as their last response assessment on prior PD-1 blockade therapy, 42% had an elevated LDH, and the median sum of the target lesions longest diameter was 6.7 cm, indicating advanced diseaseResponse rates to vidutolimod in combination with pembrolizumab were similar across baseline patient characteristics including BRAF mutation, LDH level, number of prior systemic cancer treatments, best response to prior PD-1 blockade therapy, and prior ipilimumabResponders and non-responders were not distinguished by baseline tumor characteristics including PD-L1 CPS, IFNg transcriptional signature, CD8+ T cells, or nonsynonymous mutationsAll patients showed the expected rapid induction of anti-Qb antibodies to the virus-like particle (VLP), which facilitate the pharmacodynamic response to vidutolimod, and the antibody titers were not associated with clinical responseClinical activity of vidutolimod in combination with pembrolizumab was associated with serum CXCL10 induction magnitude, induction of an inflammatory gene expression profile, and CD8+ T cells in injected and noninjected tumors “These translational data provide new insights into the rapid pharmacodynamic responses to vidutolimod and support the conclusion that clinical responses to treatment are not associated with the previously-described predictive markers for response to PD-1 blockade such as inflamed tumors,” said Dr. Jason Luke. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com. Availability of Other Information About Checkmate Pharmaceuticals Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward Looking Statements Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned clinical trials for vidutolimod (CMP-001), and the benefits and related implications of current and future partnerships and/or collaborations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Yearly Report on Form 10-K for the full year ended December 31, 2020 dated March 29, 2021, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. CONTACT: Investor Contact Rob Dolski Chief Financial Officer rdolski@checkmatepharma.com Media Contact Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com

    • 7 Beaten Down Stocks with Significant Insider Buying
      InvestorPlace

      7 Beaten Down Stocks with Significant Insider Buying

      Insiders are people who have access to private information about a company and can do something called insider buying. They include a company’s senior management, members of the board of directors and other important employees. There have been many times that insiders have used this information to profit at the expense of others. For example, if an insider knows that bad news will come out and drive the shares lower, they could sell their shares to someone who is unaware. And if the news is good and will result in a rise in price, an insider can also buy shares from an investor who doesn’t have access to this information. In order to prevent this type of unethical and illegal behavior, financial regulators have established certain rules and regulations. One is that if an insider buys or sells their company’s stock, they must disclose it to the public. This information can help regular investors find profitable investments.InvestorPlace - Stock Market News, Stock Advice & Trading Tips For example, if the share price of a company has declined and the insiders start to buy, it could be a sign that they believe the selling is overdone. 7 Great Stocks to Buy Under $10 As such, this list covers stocks that have seen significant insider buying lately. That makes them worth keeping on your radar. Rhythm Pharmaceuticals (NASDAQ:RYTM) Cyclo Therapeutics (NASDAQ:CYTH) Agile Therapeutics (NASDAQ:AGRX) Checkmate Pharmaceuticals (NASDAQ:CMPI) Gold Resource (NYSEAMERICAN:GORO) William Penn Bancorp (NASDAQ:WMPN) Windtree Therapeutics (NASDAQ:WINT) Stocks with Insider Buying: Rhythm Pharmaceuticals (RYTM) Chart by TradingView Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. Its focus is on the development and sale of therapeutics for the treatment of “rare genetic diseases of obesity.” Rhythm was founded in 2008 and is based in Boston, Massachusetts. As you can see from the above chart, RYTM stock almost reached $40 a share in January. Then it went into a steady decline. Now, it trades at around $21 per share. However, David Meeker — the president and CEO of the company — must believe that the stock will rebound. On Mar. 31, he reported buying 10,000 shares at an average price of $20.17. This case of insider buying is a personal investment of over $200,000. Wall Street also thinks that the shares are currently undervalued. According to Tipranks, six analysts following the company give it a consensus rating as a strong buy. The average target price is $49.40. That’s more than double the price RYTM is currently trading for. Cyclo Therapeutics (CYTH) Chart by TradingView Cyclo Therapeutics is another biotechnology company on this insider buying list, this time a clinical-stage one. It develops cyclodextrin-based products for the treatment of various diseases. Formerly known as CTD Holdings, Cyclo changed its name in late 2019. However, the original company was actually founded in 1990. As you can see on the chart above, like many biotech companies, shares of CYTH stock are extremely volatile. But, over the past year, the trend has been lower. Last April, shares traded around $18 a share. Now they are trading between $7 and $8. 7 Big Names That Could Be the Next Tesla That said, the insiders of this company think now is a good time to get in on CYTH. Jeffrey Tate is Chief Operating Officer. On Mar. 30, Tate filed a form with the U.S. Securities and Exchange Commission (SEC) saying he bought 2,000 shares at $7.50 a share. On the same day, another insider — Markus Sieger, a director — bought 10,000 shares at $8.10 apiece. Francis Ostronic, another director, also bought a total of 3,000 shares on the same day. Agile Therapeutics (AGRX) Chart by TradingView Agile Therapeutics (AGRX) is a women’s healthcare company that researches, develops and commercializes prescription contraceptive products. As you can see on the above chart, since the middle of February, the price of AGRX stock has declined from around $3.60 to current levels touching $2. However, three insiders have decided to take advantage of this weakness by making significant personal investments and engaging in insider buying. According to forms filed with the SEC, between Mar. 23 and Mar. 29, they acquired a total of 72,500 shares. They each paid around $2 a share. According to Tipranks, four analysts following Agile believe it is undervalued as well. The consensus rating is a strong buy. The average target price is $8.25. That is four times higher than where shares are currently trading. Checkmate Pharmaceuticals (CMPI) Chart by TradingView The next name on this insider buying list is yet another pharma company. Checkmate Pharmaceuticals is a clinical-stage biotechnology company that develops and sells therapeutics for cancer. Shares of CMPI stock declined from around $15 to about $11 recently. This was a decline of more than 25%. However, this didn’t phase Arthur Krieg, the Chief Scientific Officer at Checkmate. He must believe the selling is an overreaction. Recently, Krieg made a significant personal investment. Between Mar. 26 and Mar. 30, the officer bought a total of 46,740 shares. 7 Monthly Dividend Stocks That Pay the Bills On Tipranks, only one analyst follows Checkmate, but they consider CMPI stock undervalued. The average target price is $19. That’s over 75% higher than the current share price. Gold Resource (GORO) Chart by TradingView Gold Resource is a company that mines and sells gold and silver mainly out of Mexico. It also explores and mines copper, lead and zinc deposits. The company was founded in 1998 and is headquartered in Colorado. The gold trade isn’t working out for most investors right now. Many experts have advised to buy gold lately because they thought that the recent government stimulus package would lead to inflation. This would potentially result in the price of gold moving higher. Maybe it still will. But since August, the price has declined from around $2,000 to $1,740 an ounce today. This has caused the price of gold stocks to decline, as we have here with GORO stock. Like we’ve seen with other cases of insider buying, though, Ronald Little is a director at GORO and must believe things will turn around soon. Between Mar. 19 and March 29, Little bought a total of 40,000 shares. According to Tipranks, one analyst covering GORO stock has it rated as a buy with a target price of $5.25. That is more than 80% higher than the current price. William Penn Bancorp (WMPN) Chart by TradingView Next up on this list of insider buying stocks is William Penn Bancorporation, the holding company for William Penn Bank. The company recently announced that it would be offering more shares to the public. This caused the stock to plummet. As you can see on the above chart, the share price fell from $38 to current levels around the $11.40 mark. However, insiders are taking advantage of this recent selloff. Between Mar. 26 and Mar. 31, a number of insiders bought significant amounts of stock. Of course, this small company isn’t currently followed on Wall Street’s radar screen. None of the big research firms cover it. But that doesn’t count WMPN stock out as an investment. 7 Micro-Cap Stocks to Buy That Are Shining Right Now After all, some investors like buying stocks of companies that aren’t covered by the Street. They think that if the company is successful and gets “discovered” by Wall Street, it will boost the price of the shares. Maybe the insiders think that could happen here. Windtree Therapeutics (WINT) Chart by TradingView Last up on this list of insider buying stocks, Windtree Therapeutics is a biotechnology and medical device company that’s focused on products and treatments for acute pulmonary and cardiovascular diseases. Formerly known as Discovery Laboratories, WINT changed its name in 2016. However, the original company was incorporated in 1992. Over the past year, shareholders of WINT stock haven’t had much to be happy about. The bears have been in control of it. As you can see on the chart, the share price has steadily declined from around $10 a year ago to current levels close $2.50. But James Huang, a director of the company, must think that the selling is overdone. Huang seems to be expecting a rebound. On Mar. 31, he bought 150,000 shares at an average price of $2.36 a share. This was a personal investment of over $350,000. On the date of publication, Mark Putrino did not have any positions (either directly or indirectly) in any of the aforementioned securities. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post 7 Beaten Down Stocks with Significant Insider Buying appeared first on InvestorPlace.